Publication:
Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry.

dc.contributor.authorZeymer, Uwe
dc.contributor.authorAnnemans, Lieven
dc.contributor.authorDanchin, Nicolas
dc.contributor.authorPocock, Stuart
dc.contributor.authorNewsome, Simon
dc.contributor.authorVan de Werf, Frans
dc.contributor.authorMedina, Jesús
dc.contributor.authorBueno, Hector
dc.date.accessioned2020-10-29T14:15:24Z
dc.date.available2020-10-29T14:15:24Z
dc.date.issued2019-03
dc.description.abstractAtrial fibrillation (AF) is associated with increased morbidity in acute coronary syndrome patients, but impact on outcomes beyond 1 year is unclear. This was a post-hoc analysis from the long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients (EPICOR) registry (NCT01171404), a prospective, observational study conducted in Europe and Latin America, which enrolled acute coronary syndrome survivors at discharge. Antithrombotic management patterns, mortality, a composite endpoint of death/new non-fatal myocardial infarction/stroke and bleeding events were assessed after 2 years of follow-up in patients with or without AF. Of 10,568 patients enrolled, 397 (4.7%) had prior AF and 382 (3.6%) new-onset AF during index hospitalisation. Fewer patients with AF underwent percutaneous coronary intervention (52.1% vs. 66.6%; P<0.0001). At discharge, fewer AF patients received dual antiplatelet therapy (71.6% vs. 89.5%; P<0.0001); oral anticoagulant use was higher in AF patients but was still infrequent (35.0% vs. 2.5%; P<0.0001). Use of dual antiplatelet therapy and oral anticoagulants declined over follow-up with over 50% of all AF/no AF patients remaining on dual antiplatelet therapy (55.6% vs. 60.6%), and 23.3% (new-onset AF) to 42.1% (prior AF) on oral anticoagulants at 2 years. At 2 years, mortality, composite endpoint and bleeding rates were higher in AF patients (all P<0.0001) compared to patients without AF. On multivariable analysis, the risk of mortality or the composite endpoint was significant for prior AF ( P=0.003, P=0.001) but not new-onset AF ( P=0.88, P=0.92). Acute coronary syndrome patients with AF represent a high-risk group with increased event rates during long-term follow-up. Prior AF is an independent predictor of mortality and/or ischaemic events at 2 years. Use of anticoagulants in AF after acute coronary syndrome is still suboptimal.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: EPICOR was funded by AstraZenecaes_ES
dc.format.number2es_ES
dc.format.page121-129es_ES
dc.format.volume8es_ES
dc.identifier.citationEur Heart J Acute Cardiovasc Care. 2019; 8(2):121-129es_ES
dc.identifier.doi10.1177/2048872618769057es_ES
dc.identifier.journalEuropean heart journal. Acute cardiovascular carees_ES
dc.identifier.pubmedID29611427es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11261
dc.language.isoenges_ES
dc.publisherSAGE Publishinges_ES
dc.relation.publisherversionhttps://doi.org/10.1177/2048872618769057es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Investigación Cardiovascular Traslacional Multidisciplinariaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshRegistrieses_ES
dc.subject.meshAcute Coronary Syndromees_ES
dc.subject.meshAgedes_ES
dc.subject.meshAtrial Fibrillationes_ES
dc.subject.meshCause of Deathes_ES
dc.subject.meshEuropees_ES
dc.subject.meshFemalees_ES
dc.subject.meshFibrinolytic Agentses_ES
dc.subject.meshFollow-Up Studieses_ES
dc.subject.meshHumanses_ES
dc.subject.meshIncidencees_ES
dc.subject.meshLatin Americaes_ES
dc.subject.meshMalees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshPercutaneous Coronary Interventiones_ES
dc.subject.meshPrognosises_ES
dc.subject.meshProspective Studieses_ES
dc.subject.meshRisk Factorses_ES
dc.subject.meshSurvival Ratees_ES
dc.subject.meshThrombolytic Therapyes_ES
dc.subject.meshThrombosises_ES
dc.subject.meshTime Factorses_ES
dc.titleImpact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationee6666ff-4064-47e5-9144-afdcc607733b
relation.isAuthorOfPublication4e417023-fc1f-41d2-8130-485f76466465
relation.isAuthorOfPublication.latestForDiscoveryee6666ff-4064-47e5-9144-afdcc607733b

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
ImpactKnownNew-onsetAtrial_2019.pdf
Size:
624.19 KB
Format:
Adobe Portable Document Format
Description:
Artículo
Loading...
Thumbnail Image
Name:
ImpactKnownNew-onsetAtrial_2019_SupplMat.pdf
Size:
737.02 KB
Format:
Adobe Portable Document Format
Description:
Material suplementario